


A reliable alternative  
to permanent mesh





# A reliable alternative to permanent mesh

With rapid tissue ingrowth and long-lasting strength,<sup>1</sup> bioresorbable Phasix™ Mesh provides a strong, reliable repair when patients need it most.<sup>2</sup>



Composed of biologically-derived material, poly-4-hydroxybutyrate (P4HB)<sup>1</sup>



Organized and functional collagen at the repair site<sup>1</sup>



3x the strength of the native abdominal wall at 52 weeks<sup>1</sup>

## Improved healing from the start Predictable strength for the long run.

Phasix™ Mesh provides critical strength during the initial healing phase with rapid tissue ingrowth and vascularization through its open-pore monofilament structure, then gradually and predictably degrades within 12 to 18 months leaving behind a durable, functional repair.<sup>1</sup>

### Clinically proven long-term outcomes<sup>3</sup>

|                          | Phasix™ Mesh | Strattice™ Tissue Matrix |
|--------------------------|--------------|--------------------------|
| Total recurrence         | <b>12.9%</b> | 38.1%                    |
| Postoperative infections | <b>12.9%</b> | 31.0%                    |
| Complications            | <b>19.4%</b> | 45.0%                    |

## Backed by 5-year data

In a longitudinal 5-year follow up of 73 complex abdominal wall reconstruction patients, Phasix™ Mesh demonstrated lower recurrence, SSI and complication rates compared to Strattice™ Tissue Matrix.<sup>3</sup>

**\$10,595**  
cost savings  
associated with  
Phasix™ Mesh  
compared to  
Strattice™  
Tissue Matrix<sup>3</sup>



**BD**



# Committed partner. Full portfolio. Proven outcomes.

As the category leader for hernia repair and bioresorbable mesh, BD is committed to providing an innovative hernia portfolio that focuses on improving clinical outcomes for better patient care.



**Over 153,000  
implants<sup>4</sup>**



**More than 10  
clinical studies<sup>2</sup>**



**More than 950  
patients studied<sup>2</sup>**



**Proven clinical  
outcomes<sup>2</sup>**

| Phasix™ Mesh  |      |           |                             |
|---|------|-----------|-----------------------------|
| Ventral hernias; Onlay, retrorectus, or preperitoneal placement |      |           |                             |
| Product code  | Qty. | Shape     | Dimensions                  |
| 1190100G  | 1/cs | Round     | 3" (7.6 cm)                 |
| 1190011G  | 1/cs | Round     | 4.5" (11 cm)                |
| 1190808G  | 1/cs | Square    | 3" x 3" (8 cm x 8 cm)       |
| 1190616G  | 1/cs | Rectangle | 2.4" x 6.3" (6 cm x 16 cm)  |
| 1190816G  | 1/cs | Rectangle | 3" x 6.3" (8 cm x 16 cm)    |
| 1190820G  | 1/cs | Rectangle | 3" x 8" (8 cm x 20 cm)      |
| 1191010G  | 1/cs | Square    | 4" x 4" (10 cm x 10 cm)     |
| 1190200G  | 1/cs | Rectangle | 4" x 6" (10.2 cm x 15.2 cm) |
| 1191020G  | 1/cs | Rectangle | 4" x 8" (10 cm x 20 cm)     |
| 1191025G  | 1/cs | Rectangle | 4" x 10" (10 cm x 25 cm)    |
| 1190300G  | 1/cs | Rectangle | 6" x 8" (15.2 cm x 20.3 cm) |

|          |      |           |                               |
|----------|------|-----------|-------------------------------|
| 1191525G | 1/cs | Rectangle | 6" x 10" (15 cm x 25 cm)      |
| 1192020G | 1/cs | Square    | 8" x 8" (20 cm x 20 cm)       |
| 1191530G | 1/cs | Rectangle | 6" x 12" (15 cm x 30 cm)      |
| 1190400G | 1/cs | Rectangle | 8" x 10" (20.3 cm x 25.4 cm)  |
| 1192030G | 1/cs | Rectangle | 8" x 12" (20 cm x 30 cm)      |
| 1192040G | 1/cs | Rectangle | 8" x 16" (20 cm x 40 cm)      |
| 1190500G | 1/cs | Rectangle | 10" x 12" (25.4 cm x 30.5 cm) |
| 1193030G | 1/cs | Square    | 12" x 12" (30 cm x 30 cm)     |
| 1192540G | 1/cs | Rectangle | 10" x 16" (25 cm x 40 cm)     |
| 1193045G | 1/cs | Rectangle | 12" x 18" (30 cm x 45 cm)     |
| 1193535G | 1/cs | Square    | 14" x 14" (35 cm x 35 cm)     |
| 1194040G | 1/cs | Square    | 16" x 16" (40 cm x 40 cm)     |
| 1194545G | 1/cs | Square    | 18" x 18" (45 cm x 45 cm)     |
| 1195050G | 1/cs | Square    | 19.5" x 19.5" (50 cm x 50 cm) |



## Phasix™ Mesh

Phasix™ Mesh. **Indications:** Phasix™ Mesh is indicated to reinforce soft tissue where weakness exists in patients undergoing plastic and reconstructive surgery, or for use in procedures involving soft tissue repair, such as the repair of hernia or other fascial defects that require the addition of a reinforcing or bridging material to obtain the desired surgical result. **Contraindications:** Because Phasix™ Mesh is fully resorbable, it should not be used in repairs where permanent wound or organ support from the mesh is required. **Warnings:** Phasix™ Mesh must not be put in direct contact with bowel or viscera. The safety and product use for patients with hypersensitivities to tetracycline hydrochloride or kanamycin sulfate is unknown. Use of this device in patients with known allergies to these antibiotics should be avoided. The safety and effectiveness of Phasix™ Mesh in pregnant women, pediatric use and neural and cardiovascular tissue has not been evaluated or established. If an infection develops, treat the infection aggressively. An unresolved infection may require removal of the device. **Adverse Reactions:** Possible complications include infection, seroma, pain, mesh migration, wound dehiscence, hemorrhage, adhesions, hematoma, inflammation, allergic reaction, extrusion, erosion, fistula formation and recurrence of the hernia or soft tissue defect. Please consult package insert for more detailed safety information and instructions for use.

Phasix™ Mesh CE-Marked. **Indications:** Phasix™ Mesh is indicated to reinforce soft tissue where weakness exists in patients undergoing abdominal, plastic, and reconstructive surgery in ventral hernia repair and other abdominal fascial defect procedures. **Contraindications:** Because Phasix™ Mesh is fully resorbable, it should not be used in repairs where permanent wound or organ support from the mesh is required. Phasix Mesh is contraindicated for use in the repair of pelvic organ prolapse. Phasix Mesh is contraindicated for use in the treatment of stress urinary incontinence. **Warnings:** Phasix™ Mesh must not be put in direct contact with bowel or viscera. The safety and product use for patients with hypersensitivities to tetracycline hydrochloride or kanamycin sulfate is unknown. Use of this device in patients with known allergies to these antibiotics should be avoided. The safety and effectiveness of Phasix™ Mesh in pregnant women, pediatric use and neural and cardiovascular tissue has not been evaluated or established. If an infection develops, treat the infection aggressively. An unresolved infection may require removal of the device. **Adverse Reactions:** Possible complications may include, but are not limited to infection, seroma, pain, mesh migration, wound dehiscence, hemorrhage, adhesions, hematoma, inflammation, allergic reaction, extrusion, erosion, fistula formation and recurrence of the hernia or soft tissue defect. Please consult package insert for more detailed safety information and instructions for use.

## References

1. Data on file. Preclinical results may not correlate to clinical performance. 2. Publications available upon request. 3. Buell JF, Flaris AN, Raju S, Hauch A, Darden M, Parker GG. Long-term outcomes in complex abdominal wall reconstruction repaired with absorbable biologic polymer scaffold (Poly-4-Hydroxybutyrate). *Annals of Surgery Open*. 2021;2(1). doi:10.1097/as9.0000000000000032. 4. Data on file at BD. Phasix™ Mesh, Phasix™ ST Mesh, Phasix™ Plug, Phasix™ ST Mesh with Open Positioning System and Phasix™ ST Mesh with Echo 2™ Positioning System.



BD Switzerland Sarl, Terre Bonne Park – A4, Route De Crassier, 17, 1262 Eysins, Vaud. Switzerland.

**bd.com**

BD, the BD Logo, 3DMax, Composix, CapSure, Echo 2, Ventralight and Ventrilo are trademarks of Becton, Dickinson and Company or its affiliates. © 2023 BD. All rights reserved. 12/22. BD-83554.

